143 related articles for article (PubMed ID: 1563771)
1. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.
Fries LF; Gordon DM; Schneider I; Beier JC; Long GW; Gross M; Que JU; Cryz SJ; Sadoff JC
Infect Immun; 1992 May; 60(5):1834-9. PubMed ID: 1563771
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
Brown AE; Singharaj P; Webster HK; Pipithkul J; Gordon DM; Boslego JW; Krinchai K; Su-archawaratana P; Wongsrichanalai C; Ballou WR
Vaccine; 1994 Feb; 12(2):102-8. PubMed ID: 8147091
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
[TBL] [Abstract][Full Text] [Related]
4. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.
Egan JE; Hoffman SL; Haynes JD; Sadoff JC; Schneider I; Grau GE; Hollingdale MR; Ballou WR; Gordon DM
Am J Trop Med Hyg; 1993 Aug; 49(2):166-73. PubMed ID: 8357078
[TBL] [Abstract][Full Text] [Related]
6. Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes.
Hollingdale MR; Appiah A; Leland P; do Rosario VE; Mazier D; Pied S; Herrington DA; Chulay JD; Ballou WR; Derks T
Trans R Soc Trop Med Hyg; 1990; 84(3):325-9. PubMed ID: 2175464
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R
Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910
[TBL] [Abstract][Full Text] [Related]
8. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
[TBL] [Abstract][Full Text] [Related]
9. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers.
Calle JM; Nardin EH; Clavijo P; Boudin C; Stüber D; Takacs B; Nussenzweig RS; Cochrane AH
J Immunol; 1992 Oct; 149(8):2695-701. PubMed ID: 1401909
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection.
Sina BJ; do Rosario VE; Woollett G; Sakhuja K; Hollingdale MR
Exp Parasitol; 1993 Sep; 77(2):129-35. PubMed ID: 8375482
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant.
Hoffman SL; Edelman R; Bryan JP; Schneider I; Davis J; Sedegah M; Gordon D; Church P; Gross M; Silverman C
Am J Trop Med Hyg; 1994 Nov; 51(5):603-12. PubMed ID: 7985753
[TBL] [Abstract][Full Text] [Related]
12. Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.
Nguyen TV; Sacci JB; de la Vega P; John CC; James AA; Kang AS
Malar J; 2009 Oct; 8():235. PubMed ID: 19852802
[TBL] [Abstract][Full Text] [Related]
13. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals.
Herrington D; Davis J; Nardin E; Beier M; Cortese J; Eddy H; Losonsky G; Hollingdale M; Sztein M; Levine M
Am J Trop Med Hyg; 1991 Nov; 45(5):539-47. PubMed ID: 1951863
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
[TBL] [Abstract][Full Text] [Related]
17. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model.
Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S
Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.
Gregson AL; Oliveira G; Othoro C; Calvo-Calle JM; Thorton GB; Nardin E; Edelman R
PLoS One; 2008 Feb; 3(2):e1556. PubMed ID: 18253503
[TBL] [Abstract][Full Text] [Related]
19. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.
Sherwood JA; Copeland RS; Taylor KA; Abok K; Oloo AJ; Were JB; Strickland GT; Gordon DM; Ballou WR; Bales JD; Wirtz RA; Wittes J; Gross M; Que JU; Cryz SJ; Oster CN; Roberts CR; Sadoff JC
Vaccine; 1996 Jun; 14(8):817-27. PubMed ID: 8817830
[TBL] [Abstract][Full Text] [Related]
20. IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents.
Hickey B; Teneza-Mora N; Lumsden J; Reyes S; Sedegah M; Garver L; Hollingdale MR; Banania JG; Ganeshan H; Dowler M; Reyes A; Tamminga C; Singer A; Simmons A; Belmonte M; Belmonte A; Huang J; Inoue S; Velasco R; Abot S; Vasquez CS; Guzman I; Wong M; Twomey P; Wojnarski M; Moon J; Alcorta Y; Maiolatesi S; Spring M; Davidson S; Chaudhury S; Villasante E; Richie TL; Epstein JE
PLoS One; 2020; 15(6):e0233840. PubMed ID: 32555601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
